CLDI: AI 评分 45/100 — AI 分析 (4月 2026)

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing cell-based delivery platforms for oncolytic viruses. Their innovative approach aims to enhance efficacy and improve patient safety in cancer treatment.

Key Facts: Price: $0.28 AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Calidi Biotherapeutics is pioneering a novel approach to cancer immunotherapy through its cell-based delivery of oncolytic viruses, targeting high-grade gliomas and advanced solid tumors with its NeuroNova and SuperNova platforms, offering a potential breakthrough in efficacy and safety.

CLDI是做什么的？

Founded in 2014 and based in San Diego, California, Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to revolutionizing cancer treatment. The company focuses on developing innovative immunotherapies that harness the power of oncolytic viruses delivered via proprietary cell-based platforms. These platforms are designed to protect, amplify, and potentiate oncolytic viruses, leading to enhanced efficacy and improved patient safety. Calidi's approach involves utilizing allogeneic stem cells capable of carrying an anti-tumor payload, targeting a range of oncology indications, including high-grade gliomas and solid tumors. Calidi's lead product candidates include NeuroNova and SuperNova. NeuroNova utilizes allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas, a particularly aggressive form of brain cancer. SuperNova, on the other hand, employs allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. These innovative therapies represent a significant advancement in the field of immuno-oncology, offering the potential to overcome the limitations of traditional cancer treatments. Calidi Biotherapeutics is committed to advancing its pipeline and bringing these potentially life-saving therapies to patients in need.

CLDI的投资论点是什么？

Calidi Biotherapeutics presents a notable market position due to its innovative approach to cancer immunotherapy. The company's cell-based delivery platforms for oncolytic viruses have the potential to significantly improve treatment efficacy and patient safety. With a market capitalization of $0.01 billion, Calidi offers substantial upside potential if its clinical trials are successful. Key value drivers include the advancement of NeuroNova for high-grade gliomas and SuperNova for advanced solid tumors through clinical development. Upcoming clinical trial results and potential partnerships could serve as significant growth catalysts. The company's focus on difficult-to-treat cancers also positions it to address unmet medical needs and capture a significant share of the immuno-oncology market.

CLDI在哪个行业运营？

Calidi Biotherapeutics operates within the rapidly evolving immuno-oncology market, which is projected to experience substantial growth in the coming years. The industry is characterized by intense competition and a focus on developing novel therapies that harness the power of the immune system to fight cancer. Calidi's cell-based delivery platforms differentiate it from competitors by offering a unique approach to delivering oncolytic viruses. Competitors include companies like CANF, CMND, CNSP, KZIA, and QLGN, all of whom are striving to develop innovative cancer treatments. The success of Calidi will depend on its ability to demonstrate the safety and efficacy of its therapies in clinical trials and secure regulatory approvals.

Biotechnology

Healthcare

CLDI有哪些增长机遇？

Advancement of NeuroNova for High-Grade Gliomas: NeuroNova, Calidi's lead product candidate for high-grade gliomas, represents a significant growth opportunity. The market for glioma treatment is substantial, with limited effective therapies currently available. Successful clinical trials and subsequent regulatory approval could position NeuroNova as a leading treatment option, capturing a significant share of this market. The timeline for this growth opportunity depends on the progress of ongoing clinical trials.
Development of SuperNova for Advanced Solid Tumors: SuperNova, Calidi's second lead product candidate, targets advanced metastatic solid tumors, a large and diverse market with significant unmet medical needs. The potential for SuperNova to improve outcomes in these patients represents a substantial growth opportunity for Calidi. The timeline for this growth opportunity depends on the progress of ongoing clinical trials.
Expansion of Cell-Based Delivery Platform: Calidi's proprietary cell-based delivery platforms have the potential to be applied to a wide range of oncolytic viruses and cancer types. Expanding the application of these platforms to new targets represents a significant growth opportunity for the company. This expansion could involve developing new product candidates or partnering with other companies to utilize Calidi's technology.
Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other pharmaceutical and biotechnology companies could accelerate the development and commercialization of Calidi's therapies. These partnerships could provide access to additional funding, expertise, and resources, enhancing Calidi's growth prospects. The timing and nature of these partnerships are uncertain, but they represent a significant potential growth driver.
Securing Regulatory Approvals: Obtaining regulatory approvals for NeuroNova and SuperNova is critical for Calidi's long-term growth. Successful regulatory filings and approvals would validate the safety and efficacy of Calidi's therapies and allow them to be marketed to patients. The timeline for regulatory approvals depends on the results of clinical trials and the regulatory review process.

Calidi Biotherapeutics is a clinical-stage immuno-oncology company, indicating potential for high growth but also inherent risk.
The company's pipeline includes NeuroNova and SuperNova, targeting high-grade gliomas and advanced solid tumors, respectively.
Calidi's cell-based delivery platforms aim to enhance the efficacy and safety of oncolytic viruses.
The company was founded in 2014, suggesting a relatively young company with potential for innovation.
Calidi's headquarters are in San Diego, a hub for biotechnology companies.

CLDI提供哪些产品和服务？

Develop immunotherapies for cancer treatment
Advance allogeneic stem cells capable of carrying anti-tumor payloads
Target high-grade gliomas and solid tumors
Utilize cell-based delivery platforms to protect and amplify oncolytic viruses
Enhance efficacy and improve patient safety in cancer treatment
Develop NeuroNova for high-grade gliomas
Develop SuperNova for advanced metastatic solid tumors

CLDI如何赚钱？

Develop and commercialize cell-based immunotherapies for cancer
Generate revenue through sales of approved therapies
Partner with other companies for development and commercialization
Secure funding through grants, investments, and partnerships

Patients with high-grade gliomas
Patients with advanced metastatic solid tumors
Hospitals and cancer treatment centers
Pharmaceutical companies (potential partners)

Proprietary cell-based delivery platforms
Innovative approach to oncolytic virus delivery
Pipeline of clinical-stage product candidates
Expertise in immuno-oncology and stem cell technology

什么因素可能推动CLDI股价上涨？

Upcoming: Clinical trial results for NeuroNova in high-grade gliomas.
Upcoming: Clinical trial results for SuperNova in advanced solid tumors.
Ongoing: Potential partnerships with pharmaceutical companies.
Ongoing: Advancements in cell-based delivery technology.
Ongoing: Regulatory interactions and potential approvals.

CLDI的主要风险是什么？

Potential: Clinical trial failures could significantly impact the company's value.
Potential: Regulatory setbacks could delay or prevent the approval of therapies.
Ongoing: Competition from larger pharmaceutical companies with greater resources.
Ongoing: Dependence on securing additional funding to support operations.
Potential: Dilution of existing shareholders through future equity offerings.

CLDI的核心优势是什么？

Innovative cell-based delivery platforms
Targeted approach to oncolytic virus delivery
Pipeline of clinical-stage product candidates
Experienced management team

CLDI的劣势是什么？

Limited financial resources
Dependence on clinical trial outcomes
High regulatory hurdles
Competition from larger pharmaceutical companies

CLDI有哪些机遇？

Expansion of cell-based delivery platform to new targets
Strategic partnerships and collaborations
Securing regulatory approvals for NeuroNova and SuperNova
Growing demand for innovative cancer therapies

CLDI面临哪些威胁？

Clinical trial failures
Regulatory setbacks
Competition from existing and emerging therapies
Economic downturn

CLDI的竞争对手是谁？

Can-Fite BioPharma Ltd — Focuses on small molecule drugs for cancer and inflammatory diseases. — (CANF)
Clearmind Medicine Inc. — Develops psychedelic-assisted therapies. — (CMND)
CNS Pharmaceuticals, Inc. — Developing therapies for brain tumors. — (CNSP)
Kazia Therapeutics Limited — Developing innovative oncology therapies. — (KZIA)
Qualigen Therapeutics, Inc. — Focuses on developing therapeutics for cancer and infectious diseases. — (QLGN)

Key Metrics

Price: $0.28 (-3.58%)
Market Cap: $3.0M
MoonshotScore: 45/100

Financial Health

Gross Margin: 0.0%
Return on Equity (ROE): -4.7%
Debt-to-Equity: 0.45
Current Ratio: 2.12
Beta: 1.09

Company Profile

CEO: Eric E. Poma
Headquarters: San Diego, CA, US
Employees: 28
Founded: 2021

AI Insight

常见问题

What does Calidi Biotherapeutics, Inc. (CLDI) do?

Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage immuno-oncology company focused on developing innovative cell-based delivery platforms for oncolytic viruses. Their primary goal is to enhance the efficacy and safety of cancer treatments by utilizing allogeneic stem cells to deliver anti-tumor payloads directly to cancer cells. This targeted approach aims to improve patient outcomes, particularly in challenging cancers like high-grade gliomas and advanced solid tumors, through product candidates like NeuroNova and SuperNova.

Is CLDI stock a good buy?

Evaluating whether CLDI stock is a good buy requires careful consideration. With a market cap of $0.01 billion and a negative P/E ratio of -0.25, the company is in a high-risk, high-reward phase. The potential upside lies in the success of its clinical trials for NeuroNova and SuperNova. However, investors should be aware of the inherent risks associated with clinical-stage biotech companies, including potential clinical trial failures and regulatory hurdles. A buy decision should be based on a thorough understanding of the company's technology, pipeline, and financial position.

What are the risks of investing in CLDI?

Investing in CLDI carries several risks typical of clinical-stage biotechnology companies. A primary risk is potential dilution through future equity offerings, which could decrease the value of existing shares. The company's cash burn rate is also a concern, as it requires ongoing funding to support its operations and clinical trials. Furthermore, regulatory risks are significant, as the approval of its therapies depends on successful clinical trial outcomes and favorable regulatory review. These factors contribute to the overall risk profile of investing in CLDI.

What catalysts could move CLDI stock?

Several catalysts could potentially move CLDI stock. Upcoming clinical trial results for NeuroNova in high-grade gliomas and SuperNova in advanced solid tumors are key events to watch. Positive data from these trials could significantly boost investor confidence and drive up the stock price. Additionally, any strategic partnerships or collaborations with larger pharmaceutical companies could provide financial resources and validation of Calidi's technology, acting as a positive catalyst. Regulatory milestones, such as FDA approval for its therapies, would also be major catalysts.

What is CLDI stock price target?

As of January 31, 2026, there is no readily available analyst consensus price target for CLDI stock, likely due to its micro-cap status and early stage of development. Determining a fair value estimate would require a detailed analysis of the company's pipeline, clinical trial data, and potential market opportunities. Investors should conduct their own due diligence and consider the inherent risks and uncertainties associated with clinical-stage biotechnology companies when evaluating CLDI's potential value.